Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.

Pharmacologically, ertugliflozin is most similar to empagliflozin with regard to selectivity for SGLT2, with dapagliflozin slightly less selective and canagliflozin the least selective of the 4 drugs, 33 yet only empagliflozin was associated with an improved risk for CV death, and ertugliflozin is the only SGLT2 inhibitor of the 4 studied that failed to reach statistical significance on the prespecified kidney composite end point, although analysis of eGFR change was associated with a significant improvement by ertugliflozin.

also in 6,035 other papers